Free Trial

MoonLake Immunotherapeutics (MLTX) Competitors

MoonLake Immunotherapeutics logo
$9.52 +0.06 (+0.63%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$9.56 +0.04 (+0.47%)
As of 10/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MLTX vs. DYN, BHC, SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, and STOK

Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Dyne Therapeutics (DYN), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

MoonLake Immunotherapeutics vs. Its Competitors

Dyne Therapeutics (NASDAQ:DYN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$317.42M-$3.86-4.44
MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-3.42

Dyne Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics' return on equity of -40.98% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -64.12% -56.75%
MoonLake Immunotherapeutics N/A -40.98%-35.81%

Dyne Therapeutics currently has a consensus target price of $34.07, suggesting a potential upside of 98.99%. MoonLake Immunotherapeutics has a consensus target price of $36.00, suggesting a potential upside of 278.15%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
4 Strong Buy rating(s)
2.94
MoonLake Immunotherapeutics
2 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.07

In the previous week, MoonLake Immunotherapeutics had 28 more articles in the media than Dyne Therapeutics. MarketBeat recorded 32 mentions for MoonLake Immunotherapeutics and 4 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.63 beat MoonLake Immunotherapeutics' score of 0.12 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MoonLake Immunotherapeutics
2 Very Positive mention(s)
2 Positive mention(s)
25 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

MoonLake Immunotherapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLTX vs. The Competition

MetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$611.48M$3.46B$6.21B$10.81B
Dividend YieldN/A2.28%5.72%4.81%
P/E Ratio-3.4228.5131.5730.95
Price / SalesN/A497.40595.06133.69
Price / CashN/A46.9537.2561.86
Price / Book1.3410.4012.056.61
Net Income-$118.94M-$52.83M$3.34B$277.10M
7 Day Performance4.39%2.10%1.93%2.57%
1 Month Performance-83.11%12.33%7.77%3.79%
1 Year Performance-79.61%14.14%56.40%33.01%

MoonLake Immunotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
2.8868 of 5 stars
$9.52
+0.6%
$36.00
+278.2%
-79.4%$611.48MN/A-3.422Trending News
Analyst Forecast
DYN
Dyne Therapeutics
2.7171 of 5 stars
$17.08
+4.3%
$34.07
+99.5%
-45.0%$2.33BN/A-4.42100Analyst Forecast
BHC
Bausch Health Cos
4.6692 of 5 stars
$6.32
+4.5%
$9.00
+42.4%
-23.8%$2.24B$9.63B24.3220,700Positive News
Upcoming Earnings
Analyst Forecast
SRPT
Sarepta Therapeutics
4.5342 of 5 stars
$23.05
+2.4%
$34.42
+49.3%
-82.7%$2.20B$1.90B-26.491,372Positive News
Analyst Forecast
Gap Up
ETNB
89BIO
2.8614 of 5 stars
$14.80
+0.3%
$25.81
+74.4%
+90.3%$2.19BN/A-4.1040News Coverage
Analyst Forecast
Short Interest ↓
MESO
Mesoblast
1.9575 of 5 stars
$17.65
+3.4%
$24.00
+36.0%
+93.9%$2.18B$17.20M0.0080Analyst Forecast
OCUL
Ocular Therapeutix
4.3155 of 5 stars
$12.18
+2.9%
$22.63
+85.8%
+5.5%$2.06B$63.72M-9.52230Positive News
Analyst Forecast
ANIP
ANI Pharmaceuticals
3.8754 of 5 stars
$95.12
+0.3%
$99.14
+4.2%
+59.0%$2.06B$614.38M-123.53600News Coverage
Positive News
Analyst Upgrade
VERA
Vera Therapeutics
2.7011 of 5 stars
$30.20
-3.3%
$61.50
+103.6%
-26.6%$1.99BN/A-8.4440News Coverage
Analyst Forecast
COGT
Cogent Biosciences
2.3017 of 5 stars
$16.22
-1.0%
$19.67
+21.2%
+26.0%$1.87BN/A-9.1180News Coverage
Analyst Forecast
Gap Up
STOK
Stoke Therapeutics
3.2685 of 5 stars
$34.65
+3.3%
$30.83
-11.0%
+167.9%$1.84B$36.56M40.77100Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MLTX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners